JD Esq - Immunome General Officer
| IMNM Stock | USD 11.53 0.38 3.41% |
Executive
JD Esq is General Officer of Immunome
| Age | 51 |
| Address | 18702 N. Creek Parkway, Bothell, WA, United States, 98011 |
| Phone | 610 321 3700 |
| Web | https://immunome.com |
Immunome Management Efficiency
The company has return on total asset (ROA) of (0.3989) % which means that it has lost $0.3989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7636) %, meaning that it created substantial loss on money invested by shareholders. Immunome's management efficiency ratios could be used to measure how well Immunome manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -0.91. At this time, Immunome's Total Assets are very stable compared to the past year. As of the 27th of November 2024, Total Current Assets is likely to grow to about 151.9 M, while Net Tangible Assets are likely to drop about 10 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD MBA | Molecular Partners AG | N/A | |
| Bob Lally | Ikena Oncology | N/A | |
| MS BS | Lantern Pharma | N/A | |
| Katharine CPA | Acrivon Therapeutics, Common | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Michael Deperro | Rezolute | N/A | |
| Marianna Zipeto | Champions Oncology | N/A | |
| MS MBA | Rezolute | 50 | |
| Gianluca Fuggetta | Gain Therapeutics | 35 | |
| Priya Raina | AnaptysBio | N/A | |
| Douglas MBA | AnaptysBio | 55 | |
| Yan MBA | Adagene | 49 | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| James MD | AnaptysBio | 62 | |
| Eric Loumeau | AnaptysBio | 61 | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Michael McNamara | In8bio Inc | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| MBA III | Celcuity LLC | 63 | |
Management Performance
| Return On Equity | -2.76 | ||||
| Return On Asset | -0.4 |
Immunome Leadership Team
Elected by the shareholders, the Immunome's board of directors comprises two types of representatives: Immunome inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immunome. The board's role is to monitor Immunome's management team and ensure that shareholders' interests are well served. Immunome's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immunome's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Robinson, Chief Officer | ||
| Michael Morin, Chief Scientist | ||
| Philip Roberts, Chief Officer | ||
| Robert Lapetina, Principal Officer | ||
| JD Esq, General Officer | ||
| Purnanand Sarma, CEO Pres | ||
| Sandra Esq, Gen Officer | ||
| Bruce MD, Chief Officer | ||
| Kinney Horn, Chief Officer | ||
| Corleen Roche, Chief Officer | ||
| Robert MD, Chief Officer | ||
| Roee Shahar, Executive Commercial | ||
| Max Rosett, Principal Operations | ||
| Philip Tsai, Chief Officer | ||
| Clay Siegall, CEO President | ||
| Dennis Giesing, Chief Officer | ||
| Jack Higgins, Chief Officer |
Immunome Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immunome a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.76 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (15.06) % | ||||
| Current Valuation | 482.26 M | ||||
| Shares Outstanding | 62.42 M | ||||
| Shares Owned By Insiders | 16.77 % | ||||
| Shares Owned By Institutions | 83.47 % | ||||
| Number Of Shares Shorted | 10.67 M | ||||
| Price To Book | 3.35 X | ||||
| Price To Sales | 71.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.